TOP TEN perturbations for 1552772_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552772_at
Selected probe(set): 1552773_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552772_at (1552773_at) across 6672 perturbations tested by GENEVESTIGATOR:

AML study 1 (inv(16)/t(16;16)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.693816
Number of Samples:28 / 74
Experimental AML study 1 (inv(16)/t(16;16))
Bone marrow samples of patients with acute myeloid leukemia (AML) with genetic aberration (inv(16)/t(16;16)).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):-4.509431
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):4.4640064
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

precursor-B-ALL study 1 (t(11q23)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.3279657
Number of Samples:70 / 74
Experimental precursor-B-ALL study 1 (t(11q23))
Bone marrow samples of patients with precursor B-ALL (t(11q23)/MLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.293722
Number of Samples:36 / 74
Experimental precursor-B-ALL study 1 (t(1;19)(q23,q13))
Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

B-ALL study 1 (hyperdiploid) / normal bone marrow sample

Relative Expression (log2-ratio):-4.2651367
Number of Samples:40 / 74
Experimental B-ALL study 1 (hyperdiploid)
Bone marrow samples of patients with hyperdiploid B-ALL (hyperdiploid karyotype).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

c-ALL/pre-B-ALL study 1 / normal bone marrow sample

Relative Expression (log2-ratio):-4.2401886
Number of Samples:232 / 74
Experimental c-ALL/pre-B-ALL study 1
Bone marrow samples of patients with c-ALL/pre-B-ALL (without t(9;22)(q34,q11)/BCR-ABL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 1 (t(12;21)(p12,q22)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.2080307
Number of Samples:58 / 74
Experimental precursor-B-ALL study 1 (t(12;21)(p12,q22))
Bone marrow samples of patients with precursor B-ALL (t(12;21)(p12,q22)/TEL-AML1).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

c-ALL/pre-B-ALL study 1 (t(9;22)(q34,q11)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.1707897
Number of Samples:121 / 74
Experimental c-ALL/pre-B-ALL study 1 (t(9;22)(q34,q11))
Bone marrow samples of patients with c-ALL/pre-B-ALL (t(9;22)(q34,q11)/BCR-ABL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

sepsis study 5 / normal blood sample

Relative Expression (log2-ratio):4.062189
Number of Samples:10 / 20
Experimental sepsis study 5
Whole blood samples from patients with sepsis. All study participants were 18 years or older with a body mass index < 40 and met the ACCP/SCCM Consensus Statement criteria and had positive microbiological blood culture test results. Exclusion criteria involved any systemic immunological disorders including Systemic Lupus Erythromatosus, Crohn’s disease and Diabetes (type 1).Patients who were transplant recipients or were currently receiving chemotherapy treatment for cancer were also excluded.
Control normal blood sample
Whole blood samples from healthy volunteers without concurrent illnesses at the time of blood collection or any past history of immunological dysfunction. All study participants were 18 years or older with a body mass index < 40.